San Francisco startup Framework Therapeutics can also be focusing on an oral, at the time-daily GLP-one drug termed GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-phase study confirmed regular weight loss of around six% and it ideas to start another mi